INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Corporate insider
DC

Duncan Charles Cliff

DirectorCIK 0002130896

EDGAR filingsOpen in network
Disclosed transactions4
Buys / sells3 / 0
Max Insider Score29
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
29
DC
Duncan Charles CliffDirector
VNDAVanda Pharmaceuticals Inc.
Open-market purchase
BUY$2,847
750 sh
Nov 3, 2026Nov 5, 2026
traded Nov 3, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Vanda Pharmaceuticals Inc.Director · Apr 24, 2026
25
DC
Duncan Charles CliffDirector
VNDAVanda Pharmaceuticals Inc.
Open-market purchase
BUY
$13K
3,447 sh
Nov 4, 2026
Nov 5, 2026
traded Nov 4, 2026
+1d
SEC FORM 4

Evidence

29
DC
Duncan Charles CliffDirector
VNDAVanda Pharmaceuticals Inc.
Open-market purchase
BUY$22K
5,803 sh
Nov 5, 2026Nov 5, 2026
traded Nov 5, 2026
+0dSEC FORM 4

Evidence

9
DC
Duncan Charles CliffDirector
VNDAVanda Pharmaceuticals Inc.
Grant or award
A—
57.1K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence